Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARANASDAQ:GBIONASDAQ:GNPXNASDAQ:LEXX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$31.32$24.33M0.4123,105 shs237,144 shsGBIOGeneration Bio$0.43+1.5%$0.47$0.32▼$4.34$28.62M2.78286,200 shs316,071 shsGNPXGenprex$0.28+6.9%$0.32$0.22▼$4.09$6.88M-0.43.63 million shs1.95 million shsLEXXLexaria Bioscience$1.35-20.1%$1.48$1.15▼$4.44$29.68M0.86171,179 shs600,311 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%-1.12%-11.19%-33.99%GBIOGeneration Bio0.00%+9.51%-6.52%-54.44%-85.72%GNPXGenprex0.00%+18.67%-16.73%-59.31%-87.11%LEXXLexaria Bioscience0.00%-2.17%-22.86%-22.41%-38.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics3.7573 of 5 stars3.05.00.04.22.20.80.0GBIOGeneration Bio3.5849 of 5 stars3.54.00.00.02.73.31.3GNPXGenprex4.0099 of 5 stars3.52.00.04.73.00.01.3LEXXLexaria Bioscience2.6597 of 5 stars3.54.00.00.02.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics 2.00Hold$83.52∞ UpsideGBIOGeneration Bio 3.00Buy$7.331,617.01% UpsideGNPXGenprex 3.00Buy$10.003,411.24% UpsideLEXXLexaria Bioscience 3.00Buy$7.00418.52% UpsideCurrent Analyst Ratings BreakdownLatest GNPX, CARA, GBIO, and LEXX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/17/2025GBIOGeneration BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/14/2025GBIOGeneration BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.003/14/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00GBIOGeneration Bio$19.89M1.44N/AN/A$3.07 per share0.14GNPXGenprexN/AN/AN/AN/A$4.99 per shareN/ALEXXLexaria Bioscience$525.92K45.07N/AN/A$0.48 per share2.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%5/12/2025 (Estimated)GBIOGeneration Bio-$126.61M-$1.98N/AN/AN/A-782.86%-104.85%-49.54%5/12/2025 (Estimated)GNPXGenprex-$30.86MN/A0.00N/AN/AN/A-409.48%-269.17%5/21/2025 (Estimated)LEXXLexaria Bioscience-$5.80M-$0.59N/AN/AN/A-1,473.04%-88.88%-83.59%7/11/2025 (Estimated)Latest GNPX, CARA, GBIO, and LEXX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025N/AGNPXGenprex-$0.82N/AN/AN/AN/AN/A5/12/2025Q1 2025GBIOGeneration Bio-$0.25N/AN/AN/A$1.70 millionN/A4/14/2025Q2 2025LEXXLexaria Bioscience-$0.16-$0.15+$0.01-$0.15$0.14 million$0.17 million3/19/2025Q4 2024GBIOGeneration Bio-$0.31-$0.32-$0.01-$0.32$2.92 million$4.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/AGBIOGeneration BioN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.774.71GBIOGeneration BioN/A6.346.34GNPXGenprexN/A0.860.86LEXXLexaria BioscienceN/A29.6229.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%GBIOGeneration Bio95.22%GNPXGenprex14.05%LEXXLexaria Bioscience13.06%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics3.10%GBIOGeneration Bio21.10%GNPXGenprex8.47%LEXXLexaria Bioscience26.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics804.57 million4.43 millionOptionableGBIOGeneration Bio15067.01 million52.70 millionOptionableGNPXGenprex2024.15 million7.79 millionNo DataLEXXLexaria Bioscience717.56 million12.92 millionNot OptionableGNPX, CARA, GBIO, and LEXX HeadlinesRecent News About These CompaniesLexaria Bioscience prices 2M shares at $1.00 in registered direct offeringApril 26 at 7:52 AM | markets.businessinsider.comLexaria Announces $2 Million Registered Direct Offering of Common StockApril 25 at 8:00 AM | thenewswire.comLexaria Announces $2 Million Registered Direct Offering of Common StockApril 25 at 8:00 AM | accessnewswire.comLexaria provides GLP-1 update following industry developmentsApril 23, 2025 | markets.businessinsider.comRecent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s TechnologyApril 23, 2025 | finance.yahoo.comRecent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's TechnologyApril 23, 2025 | accessnewswire.comWe Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth CarefullyApril 5, 2025 | uk.finance.yahoo.comLexaria Updates its Ongoing Human Study GLP-1-H24-4April 3, 2025 | thenewswire.comLexaria Updates its Ongoing Human Study GLP-1-H24-4April 3, 2025 | accessnewswire.comLexaria Bioscience begins dosing for GLP-1 study #5April 3, 2025 | markets.businessinsider.comLexaria's Human GLP-1 Study #5 Begins DosingApril 2, 2025 | accessnewswire.comLexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable ZepboundMarch 18, 2025 | thenewswire.comLexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)March 18, 2025 | accessnewswire.comLexaria Bioscience Corp.: The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria BioscienceFebruary 27, 2025 | finanznachrichten.deThe Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria BioscienceFebruary 27, 2025 | thenewswire.comThe Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria BioscienceFebruary 27, 2025 | accessnewswire.comLexaria Bioscience Corp.: Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-ArmFebruary 24, 2025 | finanznachrichten.deEthics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-ArmFebruary 24, 2025 | thenewswire.comEthics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-ArmFebruary 24, 2025 | accessnewswire.comLexaria's Strategic Business Pursuit of DehydraTECH-LiraglutideFebruary 20, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNPX, CARA, GBIO, and LEXX Company DescriptionsCara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Generation Bio NASDAQ:GBIO$0.43 +0.01 (+1.55%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.43 +0.00 (+0.21%) As of 04/25/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Genprex NASDAQ:GNPX$0.28 +0.02 (+6.87%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.28 0.00 (-0.28%) As of 04/25/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Lexaria Bioscience NASDAQ:LEXX$1.35 -0.34 (-20.12%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.28 -0.07 (-5.11%) As of 04/25/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
